Core Insights - Novo Nordisk A/S is recognized as one of the best bargain stocks to buy in November, with a focus on the US market to drive sales growth for its obesity drug Wegovy [1] - The Novo Nordisk Foundation, the company's top investor, has taken control of the board to enhance consumer-facing strategies and address competition from Eli Lilly and cheaper alternatives [2] Company Overview - Novo Nordisk A/S is a global leader in treating diabetes and obesity, with a significant historical focus on insulin production and a dominant market share [3] - The company's key growth segment is obesity treatment, particularly through its product Wegovy, which has shown high effectiveness in weight reduction [3] - Novo Nordisk has a highly integrated production process, from molecule development to automated filling lines, and distributes products globally to over 170 countries [3] Competitive Landscape - The primary competitor for Novo Nordisk is Eli Lilly, creating a duopoly in the modern treatment of diabetes and obesity [3] - The industry has extremely high barriers to entry due to long development times, regulatory challenges, and substantial investments required for production and distribution [3]